Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simulation of Nasal Glucagon vs Injectable Glucagon Administration
NCT03765502Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Trained Users That Performed a Successful Administration for Each Device. Started Nov 2018; status: completed.
Beyond the preview
Go deeper on NCT03765502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765502.